Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 Phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
J Am Acad Dermatol 2018;79:302–14. doi: 10.1016/j.jaad.2018.04.012
Treatment of moderate-to-severe chronic plaque PsO with either CZP 400 mg or 200 mg Q2W was associated with significant, clinically meaningful improvements in efficacy and quality of life that were maintained over time compared with placebo. Safety findings were in line with those expected of the therapy.
Both CIMPASI-1 and CIMPASI-2 assessed the efficacy and safety of CZP compared with placebo for the treatment of moderate to severe chronic plaque PsO.
Keywords:
